Sab Biotherapeutics Inc (SABS) — Who's Buying and Selling (13F, Q2 2026)

SABS ranks #4886 out of 37696 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

88 institutions disclose a position in SABS, but none treat it as a major bet — even Vivo Capital, LLC, its most concentrated holder, allocates just 2.6% of its own portfolio to it.

SABS is down 5.3% today, but institutions show net buying of $15.7M this quarter — a divergence between today's price move and the underlying institutional flow.

SABS reported a net loss of $12.8M over the trailing twelve months.

• Not yet profitable — net loss of $12.8M over the trailing twelve months
• Revenue declined 40.9% year over year
• Net income improved year over year, from -$37.1M to -$12.8M
• Operating cash flow was negative, using $44.8M in cash
• Current ratio of 9.46x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.14x equity — within a conventional range